A new exploratory pilot study published in BMC Women’s Health investigated cervicovaginal zinc and copper levels across different vaginitis phenotypes. The findings suggest that trace-metal profiles vary with vaginal health and infection type, with the highest zinc and copper concentrations observed in fungal vaginitis. The study also provides a hypothesis-generating rationale for further clinical research into zinc-containing vaginal hydrogels as an adjunct to standard antifungal therapy. JUVIAGEL, Fempharma’s zinc-containing vaginal hydrogel, was the investigational hydrogel used in the study, further strengthening the scientific foundation supporting its continued clinical development. It is open access by clicking here.

Recent scientific publications have investigated the potential role of zinc in vaginal tissue physiology and vulvovaginal health. A recent systematic review and meta-analysis published in BMC Infectious Diseases evaluated available clinical, observational, and mechanistic studies related to zinc and vulvovaginal candidiasis (VVC).

The review summarized evidence suggesting that women with recurrent vulvovaginal candidiasis may exhibit lower systemic zinc levels compared to healthy controls. Experimental studies discussed in the review also reported that zinc may influence inflammatory pathways and fungal virulence mechanisms associated with vulvovaginal candidiasis.

Additional preclinical studies have demonstrated that zinc may contribute to extracellular matrix physiology in vaginal tissue by influencing collagen and elastin production in human vaginal smooth muscle cells.

These findings contribute to the growing scientific interest in local vaginal zinc delivery approaches and support further investigation of zinc-containing vaginal formulations.. It is open access by clicking here

Our latest study has been published at the BMC Women’s Health titled “Cervicovaginal lavage fluid iron and manganese levels in women with and without vaginitis” presenting new findings on the role of trace elements in vaginal health and inflammation. The study showed that women with culture-positive vaginitis had significantly higher cervicovaginal iron levels, while adjunct treatment with JUVIAGEL – our zinc-containing intravaginal hydrogel – appeared to moderate this increase, supporting improved mucosal integrity and reduced inflammation-related iron availability. It is open access by clicking here.

We are proud to announce that our U.S. patent US 12,268,712B2 has officially been granted. This milestone recognizes our innovation and dedication in the field of women’s health and specifically postnatal regeneration. The newly granted patent strengthens our intellectual property portfolio and supports the continued development of our flagship product Mommytoo. It also opens new opportunities for partnerships and global expansion. We thank our talented team and collaborators for their relentless efforts in making this achievement possible.

Our abstract entitled “Improving Vaginal Health With a Zinc-Containing Vaginal Hydrogel: A Prospective Cohort Study” has been selected as a Moderated E-Poster/Scientific Salon Presentation at the IUGA/EUGA Joint Meeting 2025.

Join us on June 18-21, 2025 in Barcelona: www.iugaeuga2025.org.

In a paper, published in Gels (an MDPI journal), we have showed JUVIAGEL’s role as an effective, nonhormonal, drug-free, and local adjunct treatment for a variety of vulvovaginal symptoms. The article is available as an Open Access at https://www.mdpi.com/2310-2861/11/3/214

In a paper, published in Science Translational Medicine, we have showed that JUVIAGEL could be effective against recurrent yeast infections. More in our Press Release.

Fempharma has a successful exhibition at CPhI Barcelona 2023.

Fempharma has been successfully audited for ISO 13485:2016 Manufacturing and Trade of Medical Devices by Tequa-Zert, a TÜV Hessen partner.

We have presented our latest study “A randomized controlled pilot trial to assess the effectiveness of a specially formulated food supplement and pelvic floor muscle training in women with stress-predominant urinary incontinence.” at the International Urogynecological Association’s (IUGA) 48th Annual Meeting on June 24, 2023 in The Hague, The Netherlands.

You can find our abstract at URO TODAY Magazine.

Our latest study about the efficacy of INCOXIL has been published at the BMC Women’s Health titled “A randomized controlled pilot trial to assess the effectiveness of a specially formulated food supplement and pelvic floor muscle training in women with stress-predominant urinary incontinence”. It is open access by clicking here.

We have presented our latest study “A randomized controlled trial to assess the effectiveness of a specially formulated food supplement and pelvic floor muscle training in women with stress-predominant urinary incontinence” at the American College of Obstetricians and Gynecologists (ACOG) 2023 Annual Clinical & Scientific Meeting in Baltimore, MD.

You can find our abstract at Obstetrics & Gynecology (the Green Journal)

New clinical trial for Juvia has started. Vaginitis is one of the most common gynecological problems in women. Candida albicans is responsible for more than 85% of vaginal fungal infections and reinfection after standard treatment is quite common. The aim of this study is to compare the effects of Juvia vaginal gel and oral fluconazole on the treatment and recurrence of vulvovaginal candidiasis (VVC). Our hypothesis is that Juvia vaginal gel may decrease the rate of reinfection after standard treatment with oral 150 mg fluconazole.

Fempharma’s proprietary vaginal moisturizer gel JUVIA has gotten into the shelves at Rossmann Hungary.

Fempharma has been successfully audited for ISO 22000:2018 research and development, contract manufacturing of dietary supplements.